The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice

Cardiovascular Research

Volumn 44, Issue 3, 1999, Pages 579-587

  Hayek, Tony ^a   Attias, Judith ^a   Coleman, Raymond ^a   Brodsky, Sergey ^a   Smith, Jonathan ^b   Breslow, Jan L ^b   Keidar, Shlomo ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Angiotensin II; Apo E deficient mice; Atherosclerosis; Blood pressure; LDL oxidation

Indexed keywords

ANGIOTENSIN ANTAGONIST; COPPER SULFATE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; HYDROPEROXIDE DERIVATIVE; LIPID PEROXIDE; LOSARTAN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CONTROLLED STUDY; DRUG MECHANISM; HYPERLIPOPROTEINEMIA TYPE 3; LIPID OXIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; DRUG ADMINISTRATION SCHEDULE; FOSINOPRIL; HYDRALAZINE; HYPERTENSION; LIPID PEROXIDATION; LIPOPROTEINS, LDL; LOSARTAN; MICE; MICE, TRANSGENIC; OXIDATION-REDUCTION; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN;

EID: 0033408540     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00239-4     Document Type: Article

References (56)

1. Geisterfer A, Peach M, Owens G. Angiotensin II induces hypertrophy of cultured rat aortic smooth muscle cells. Circ Res 1988;62:749-756.
2. Campbell-Boswell M, Robertson A. Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol 1981;35:265-273.
3. Daemon M, Lombardi D, Bosman F, Schwartz S. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-456.
4. Wolf G, Haberstroh U, Neilson E. Angiotensin II stimulates the proliferation and biosynthesis of type-I collagen in cultured murine mesangial cells. Am J Pathol 1992;140:95-107.
5. Katoh H, Suzuki H, Ogata Y. Angiotensin II stimulates collagen and fibronectin synthesis in cultured vascular smooth muscle cells. Clin Exp Hyperten 1990;12:675-688.
6. Yusuf S, Pepine CJ, Garces H. Effect of enalapril on myocardial infarction and unstable angina pectoris in patients with low ejection fraction. Lancet 1992;340:1173-1179.
7. Pfeffer MA, Braunwald E, Moye LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677.
8. Chobanian A, Handenschild C, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-331.
9. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990;15:565-572.
10. Charpiot P, Rolland PH, Friggi A. ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries. Arterioscler Thromb 1993;13:1125-1138.
11. Rolland PH, Souchet T, Friggi A. Angiotensin converting enzyme inhibition-induced changes in patterns of hemodynamics, aorta viscoelasticity, arterial histopathology and endothelial cholesterol fluxes of atherosclerotic minipigs. J Hypertension 1991;9:S178-S179.
12. Kowala M, Grove R, Aberg G. Inhibitors of angiotensin-converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinorpil reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 1994;108:61-72.
13. Keidar S, Oiknine J, Leiba A et al. Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients. J Cardiovasc Pharmacol 1996;27:183-186.
14. Ridker P, Gaboury C, Conlin P et al. Stimulation of PAI in vivo by infusion of angiotensin: Evidence of potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-1973.
15. Keidar S, Brook JG, Aviram M. Angiotensin II enhances lipid peroxidation of low density lipoprotein. News Physiol Sci 1993;8:245-248.
16. Hayek T, Attias J, Smith J, Breslow JL, Keidar S. Antiatherosclerotic and antioxidative effects of Captopril in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 1998;31:540-544.
17. Parathasarathy S, Steinberg D, Witztum JL. The role of oxidized LDL in the pathogenesis of atherosclerosis. Ann Rev Med 1992;43:219-225.
18. Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis 1993;98:1-9.
19. Witztum JL, Steinberg D. Role of oxidized LDL in atherogenesis. J Clin Invest 1991;88:1785-1791.
20. Steinberg D, Parathasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of LDL that increase its atherogenicity. N Engl J Med 1989;320:915-924.
21. Aviram M. LDL modification by cholesterol oxidase induces enhanced uptake and cholesterol accumulation in cells. J Biol Chem 1992;267:218-225.
22. Hayek T, Oiknine J, Brook JG, Aviram M. Increased plasma and lipoprotein lipid peroxidation in apo E deficient mice. Biochem Biophys Res Comm 1994;201:1567-1574.
23. Maor J, Aviram M. Oxidized LDL leads to macrophage accumulation of unesterified cholesterol as a result of lysosomal trapping of the lipoprotein hydrolyzed cholesteryl ester. J Lipid Res 1994;35:803-819.
24. Keidar S, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-mediated lipid peroxidation of LDL. Atherosclerosis 1995;115:201-215.
25. Keidar S, Kaplan M, Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol 1996;16:97-105.
26. Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M. LDL isolated from patients with essential hypertension exhibit increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 1994;107:71-84.
27. Schuh J, Blehmn D, Friedrich G, McMahon E, Blaine E. Differential effects of renin-angiotensin blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 1993;91:1453-1458.
28. Albaladejo P, Bouaziz H, Duriez M et al. ACE inhibition prevents the increase in aortic collagen in rats. Hypertension 1994;23:74-82.
29. Linz W, Jessen T, Becher R, Scholkens B, Wiener G. Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation 1997;96:3164-3172.
30. Timmermans P, Wong P, Chiu AT. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251.
31. Urata H, Nishimura H, Ganten D. Chymase-dependent angiotensin II forming system in humans. Am J Hypertens 1996;9:277-284.
32. Urata H, Boehm K, Philip A. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993;91:1269-1281.
33. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Comm 1997;236:622-625.
34. Plump A, Smith J, Hayek T et al. Severe hypercholesterolemia and atherosclerosis in apo E deficient mice created by homologous recombinant ES cells. Cell 1992;71:343-353.
35. Zhang SH, Reddick RL, Piedrahita J, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992;258:468-471.
36. Nakashima Y, Plump A, Raines E, Breslow JL, Ross R. Apo E deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994;14:133-139.
37. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E: Evaluation of lesional development and progression. Arterioscler Thromb 1994;14:141-148.
38. Holmquist B, Bunn P, Riordan J. A spectrometric assay for angiotensin-converting enzyme. Anal Biochem 1979;95:540-544.
39. Lowry OH, Rosebrough NJ, Farr L, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-275.
40. Buege L, Aust S. Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-310.
41. Halliwell B, Guttridge JM. Role of iron in oxygen radical reactions. Methods Enzymol 1984;105:47-56.
42. Jamieson M, Gonzales G, Jackson T, Shepherd A. Evaluation of the IITC tail cuff blood pressure recorder in the rat against intraarterial pressure according to criteria of human devices. Am J Hypertension 1997;10:209-213.
43. Handelman G, Frankel E, Fenz R, German JR. Chemical changes during the early phase of in vitro oxidative damage to human LDL. Biochem Molec Biol Int 1993;31:777-788.
44. Goetzl E, Klickstein LB, Watt K, Wintroub B. The preferential human mononuclear leukocyte chemotactic activity of the substituent tetrapeptides of angiotensin II. Biochem Biophys Res Comm 1980;97:1097-1102.
45. Allemann Y, Baumann S, Jost M. Insulin sensitivity in normotensive subjects during ACE inhibition with fosinopril. Eur J Clin Pharmacol 1992;42:275-280.
46. Keidar S. Angiotensin, lipid peroxidation and atherosclerosis-minireview. Life Sci 1998;63:1-11.
47. Aviram M, Maor I, Keidar S et al. Lesioned LDL in atherosclerotic apo E deficient mice and in humans is oxidized and aggregated. Biochem Biophys Res Comm 1995;216:501-513.
48. Maor I, Hayek T, Coleman R, Aviram M. Plasma LDL oxidation leads to its aggregation in the atherosclerotic apo E deficient mice. Arterioscler Thromb 1997;17:2995-3005.
49. Stephens N, Parsons A, Schofield P et al. Randomised controlled trial of vitamin E in patients with CAD: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-786.
50. Robertson W, Strong J. Atherosclerosis in persons with hypertension and diabetes mellitus. Lab Invest 1968;18:538-551.
51. Chobanian A, Lichtenstein A, Nilakhe V et al. Influence of hypertension on aortic atherosclerosis in the Watanabe rabbit. Hypertension 1989;14:203-209.
52. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke and coronary heart disease. Lancet 1990;335:765-774.
53. Lutscher T, Vanhoutte P. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986;8:34-38.
54. Panza J, Quyumi A, Brush J, Epstein S. Abnormal endothelium-dependent vascular reactions in patients with essential hypertension. N Engl J Med 1990;323:22-27.
55. Schwartz S, Campbell G, Campbell J. Replication of smooth muscle cells in vascular disease. Circ Res 1986;41:248-255.
56. Chobanian A, Hope S, Brecher P. Dissociation between the antiatherosclerotic effect of trandolapril and suppression of serum and aortic ACE activity in WHHL rabbits. Hypertension 1995;25:1306-1310.